Gilead Sciences

Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
legal
HIV
antitrust
Flag link:
Gilead picks former Roche executive to run cell therapy unit Kite
Gilead picks former Roche executive to run cell therapy unit Kite
BioPharma Dive
Gilead Sciences
Roche
Kite Pharma
cell therapy
Cindy Perettie
women executives
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Gilead notches trial win in high-stakes HIV patent case against US government
Gilead notches trial win in high-stakes HIV patent case against US government
Fierce Pharma
Gilead Sciences
Truvada
HIV
Descovy
legal
patents
Flag link:
After FDA rejection, Gilead nears full EU nod for hep D drug
After FDA rejection, Gilead nears full EU nod for hep D drug
Pharmaphorum
Gilead Sciences
hepatitis D
FDA
Europe
Hepcludex
buleviritide
Flag link:
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
Motley Fool
Gilead Sciences
Flag link:
Gilead, US government set for courtroom showdown over PrEP drug patents
Gilead, US government set for courtroom showdown over PrEP drug patents
Fierce Pharma
Gilead Sciences
legal
patents
Truvada
Descovey
PrEP
Flag link:
Q1 revenues slide for Amgen, Gilead
Q1 revenues slide for Amgen, Gilead
Medical Marketing and Media
Amgen
Gilead Sciences
earnings
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
Gilead gets big $175m judgment in HIV fraud case
Gilead gets big $175m judgment in HIV fraud case
Pharmaphorum
Gilead Sciences
HIV
fraud
legal
reimbursement
Flag link:
Gilead plans to invest $47M+ to boost its capacity in southern Ireland
Gilead plans to invest $47M+ to boost its capacity in southern Ireland
Endpoints
Gilead Sciences
Ireland
Flag link:
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Big Pharma
Novo Nordisk
Moderna Therapeutics
Gilead Sciences
BeiGene
Flag link:
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
EP Vantage
GSK
Gilead Sciences
CROI
Cabenuva
HIV
Flag link:
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
Yahoo/Reuters
GSK
HIV
ViiV Healthcare
Gilead Sciences
Cabenuva
Biktarvy
Flag link:
Gilead Sciences reports positive data from HIV therapy trial
Gilead Sciences reports positive data from HIV therapy trial
Clinical Trials Arena
Gilead Sciences
lenacapavir
HIV
clinical trials
Flag link:

Pages